Generate Biomedicines and Zealand Pharma enter collaboration for AI-engineered protein therapeutics
FROM THE WIRE · FINANCE.YAHOO.COM
Generate Biomedicines, Inc. Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe partnership combines metabolic health expertise with generative AI platform; relevant for both partners but not sector-moving.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Generate will receive $30M upfront, up to $35M in early preclinical milestones, and up to nearly $1.2B in total milestones.
- 02The collaboration combines Zealand Pharma's metabolic health expertise with Generate's proprietary generative AI platform.
- 03The agreement will broaden Zealand Pharma's modality capabilities beyond peptides and extend Generate's platform into obesity and metabolic…
- 04The agreement includes an option to add a third program beyond the two initial programs.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Generate Biomedicines, Inc.12.26 USDMarket closedtoday -11.45%Positive Zealand Pharma A/S17.59 USDMarket closedtoday 0.00%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets